6-溴-2-萘甲醇 | 100751-63-1

• 物质功能分类: 化学试剂 - 有机试剂 - 多环化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 6-溴-2-萘甲醇
• 中文别名: 6-溴-2-萘基甲醇；(6-溴萘-2-基)甲醇
• 英文名称: (6-bromo-2-naphthy)methanol
• 英文别名: (6-bromonaphthalen-2-yl)methanol；6-bromo-2-(hydroxymethyl)naphthalene
• CAS: 100751-63-1
• 化学式: C₁₁H₉BrO
• 分子量: 237.096
• InChiKey: MAARRMBCEFVKNV-UHFFFAOYSA-N

物化性质

• 熔点：
  152-153℃
• 沸点：
  374.6±17.0 °C(Predicted)
• 密度：
  1.544±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于二甲基亚砜，二甲基亚砜、DMF、乙酸乙酯

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302
• 储存条件：
  存储条件：室温、干燥密封

反应信息

• 作为反应物：
  描述：

  6-溴-2-萘甲醇 在 哌啶 、 三叔丁基膦 、 palladium diacetate 、 caesium carbonate 、 pyridinium chlorochromate 作用下， 以 四氢呋喃 、 二氯甲烷 、 甲苯 为溶剂， 反应 98.0h， 生成 (E)-2-(2-(2-methoxyethoxy)ethoxy)ethyl-2-cyano-3-(2-(piperidin-1-yl)napthalen-6-yl) acrylate
  参考文献：
  名称：

  Aminonaphthalene 2-Cyanoacrylate (ANCA) Probes Fluorescently Discriminate between Amyloid-β and Prion Plaques in Brain

  摘要：

  A major challenge for diagnosing and monitoring the progression of amyloid-based diseases is the capability to distinguish between amyloid deposits that are associated with related, but distinctly different, diseases. Here, we demonstrate that aminonaphthalenyl 2-cyanoacrylate-based probes can fluorescently discriminate between different types of amyloid deposits in brain. The discriminating capability of these molecular rotors is due to the stabilization of the ground versus excited states of these probes as a function of the polarity of their microenvironment (i.e., within the binding pocket on the amyloid). This property makes it possible, for the first time, to estimate the inherent static relative permittivity (epsilon(0)) of the binding pocket of each amyloid within tissue. The capability to selectively follow the deposition of specific amyloids in tissue may provide important information for therapeutic development that is not readily accessible from currently available technology.

  DOI：

  10.1021/ja3063698
• 作为产物：
  描述：

  2,6-二溴萘 在 甲醇 、 sodium tetrahydroborate 、 正丁基锂 作用下， 以 四氢呋喃 为溶剂， 反应 4.5h， 生成 6-溴-2-萘甲醇
  参考文献：
  名称：

  使用π扩展亲电试剂的无环酯的对映选择性α-苄基化

  摘要：

  报道了无环酯的第一次不对称协作路易斯碱/钯催化的苄基烷基化。该反应通过立体定义的C1-烯醇铵盐亲核试剂进行。成功的关键是鉴定具有独特反应性的磷酸苄基亲电试剂。获得的烷基化产物具有很高的对映选择性，该方法已应用于凝血酶抑制剂DX‐9065a的合成。

  DOI：

  10.1002/anie.201806742

文献信息

• Heterocyclic derivatives for the treatment of cancer and other proliferative diseases
  申请人：——

  公开号：US20020143182A1

  公开（公告）日：2002-10-03

  The invention relates to certain heterocyclic compounds useful for the treatment of cancer and other diseases, having the Formula (I): 1 wherein: (a) m is an integer 0 or 1; (b) R 12 is an alkyl, a substituted alkyl, a cycloalkyl, a substituted cycloalkyl, a heterocyclic, a substituted heterocyclic, a heteroaryl, a substituted heteroaryl, an aryl or a substituted aryl residue; (c) Ar 3 is an aryl, a substituted aryl, a heteroaryl or a substituted heteroaryl residue; (d) Ar 4 is an aryl, a substituted aryl, a heteroaryl or a substituted heteroaryl residue; (e) R 5 is hydrogen, hydroxy, alkyl or substituted alkyl; (f) - - - - - represents a bond present or absent; and (g) W, X, Y and Z are independently or together C(O)—, C(S), S, O, or NH; or a pharmaceutically acceptable salt thereof.

  该发明涉及某些对治疗癌症和其他疾病有用的杂环化合物，其具有以下式（I）： 1 其中： (a) m是整数0或1； (b) R12是烷基，取代烷基，环烷基，取代环烷基，杂环基，取代杂环基，杂芳基，取代杂芳基，芳基或取代芳基残基； (c) Ar3是芳基，取代芳基，杂芳基或取代杂芳基残基； (d) Ar4是芳基，取代芳基，杂芳基或取代杂芳基残基； (e) R5是氢，羟基，烷基或取代烷基； (f) - - - - - 代表存在或不存在的键；以及 (g) W、X、Y和Z独立或一起是C(O)、C(S)、S、O或NH；或其药学上可接受的盐。
• Synthesis and Antifungal Activities of R-102557 and Related Dioxane-Triazole Derivatives.
  作者：Sadao OIDA、Yawara TAJIMA、Toshiyuki KONOSU、Yoshie NAKAMURA、Atsushi SOMADA、Teruo TANAKA、Shinobu HABUKI、Tamako HARASAKI、Yasuki KAMAI、Takashi FUKUOKA、Satoshi OHYA、Hiroshi YASUDA

  DOI：10.1248/cpb.48.694

  日期：——

  Novel triazole compounds with a dioxane ring were synthesized. Condensation of the diol precursor 10 with various aromatic aldehydes 11-13 under acidic conditions afforded a series of dioxane-triazole compounds 14-16. The antifungal activities of the compounds 14-16 were evaluated in vivo in mice infection models against Candida and Aspergillus species. High activities were seen for the derivatives with one or two double bond(s) and an aromatic ring substituted with an electron-withdrawing group in th side chain. Among the derivatives, R-102557 (16R : Ar=4-(2, 2, 3, 3)-tetrafluoropropoxy)phenyl)showed excellent in vivo activities against Candida, As-pergillus and Cryptococcus species. It also showed high tolerance in a preliminary toxicity study in rats.

  具有二噁烷环的新型三唑化合物被合成。在酸性条件下，二醇前体10与各种芳香醛11-13缩合，得到了一系列二噁烷-三唑化合物14-16。这些化合物14-16的抗真菌活性通过在小鼠感染模型中对白色念珠菌和曲霉菌的评估进行了体内评价。含有单个或两个双键且侧链上带有吸电子基团的芳环衍生物表现出较高的活性。在这些衍生物中，R-102557（16R：Ar=4-（2,2,3,3-四氟丙氧基）苯基）对白色念珠菌、曲霉菌和隐球菌属表现出极佳的体内活性。在大鼠的初步毒性研究中也显示出高度耐受性。
• Design, synthesis and biological evaluation of GPR55 agonists
  作者：Lara Fakhouri、Christopher D. Cook、Mohammed H. Al-Huniti、Linda M. Console-Bram、Dow P. Hurst、Michael B.S. Spano、Daniel J. Nasrallah、Marc G. Caron、Larry S. Barak、Patricia H. Reggio、Mary E. Abood、Mitchell P. Croatt

  DOI：10.1016/j.bmc.2017.06.016

  日期：2017.8

  consisted of coupling a variety of p-aminophenyl sulfonamides to isothiocyanates to form acylthioureas. For the synthesis of a known naphthyl ethyl alcohol motif, route modification led to a shorter and more efficient process. The 22 analogues were analyzed for their ability to serve as agonists at GPR55 and valuable information for both ends of the molecule was ascertained.

  GPR55是一种G蛋白偶联受体，是缓解炎症和神经性疼痛并治疗骨质疏松症和癌症的诱人靶标。鉴定有效和选择性的配体将有助于进一步确立受体的特定生理作用和药理作用。为了实现这一目标，以模块方式合成了22种化合物的目标库，以获得结构活性关系信息。一般路线包括耦合各种p-氨基苯基磺酰胺形成异硫氰酸酯，形成酰基硫脲。为了合成已知的萘乙醇基序，路线修饰导致了更短且更有效的过程。分析了22种类似物在GPR55上充当激动剂的能力，并确定了该分子两端的有价值的信息。
• AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME
  申请人：The Regents of the University of California

  公开号：US20180327373A1

  公开（公告）日：2018-11-15

  Provided herein is the design and synthesis of novel molecular rotor fluorophores useful for detection of amyloid or amyloid like proteins. The fluorophores are designed to exhibit enhanced fluorescence emission upon associating with amyloid or amyloid like proteins as compared to unbound compound. Also disclosed herein are methods for treating diseases associated with amyloid or amyloid like proteins.

  本文提供了用于检测淀粉样或类淀粉蛋白的新型分子转子荧光团的设计和合成。这些荧光团被设计为与淀粉样或类淀粉蛋白结合时，与未结合化合物相比表现出增强的荧光发射。本文还披露了治疗与淀粉样或类淀粉蛋白相关疾病的方法。
• Comprehensive structure-activity-relationship of azaindoles as highly potent FLT3 inhibitors
  作者：Sebastian H. Grimm、Berend Gagestein、Jordi F. Keijzer、Nora Liu、Ruud H. Wijdeven、Eelke B. Lenselink、Adriaan W. Tuin、Adrianus M.C.H. van den Nieuwendijk、Gerard J.P. van Westen、Constant A.A. van Boeckel、Herman S. Overkleeft、Jacques Neefjes、Mario van der Stelt

  DOI：10.1016/j.bmc.2019.01.006

  日期：2019.3

  Acute myeloid leukemia (AML) is characterized by fast progression and low survival rates, in which Fms-like tyrosine kinase 3 (FLT3) receptor mutations have been identified as a driver mutation in cancer progression in a subgroup of AML patients. Clinical trials have shown emergence of drug resistant mutants, emphasizing the ongoing need for new chemical matter to enable the treatment of this disease

  急性髓细胞性白血病（AML）的特征是进展快，生存率低，其中已将Fms样酪氨酸激酶3（FLT3）受体突变确定为AML患者亚组中癌症进展的驱动程序突变。临床试验已显示出耐药突变体的出现，强调了对新化学物质的持续需求，以使该疾病得以治疗。在这里，我们介绍了已知的PKA抑制剂异喹啉磺酰胺H-89作为FLT3抑制剂的类似物的发现和拓扑结构-活性关系（SAR）研究。令人惊讶地，我们发现SAR与在PKA中观察到的H-89的结合模式不一致。匹配的分子对分析导致鉴定出高活性的亚纳摩尔氮杂吲哚作为新型的FLT3抑制剂。